AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

AIC Genotyping Study

Recruitingn/aAges 18 Years - anyAllBarts & The London NHS Trust
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive/negative controls

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
INCLUSION: AIC (Cases): * Age โ‰ฅ18 * Persistent AF before index catheter ablation or cardioversion * LVEF โ‰ค40% during rate-controlled (resting HR \<100bpm, mean HR on 24-hour Holter \<100bpm) AF prior to index catheter ablation or cardioversion * LVEF normalisation (LVEF โ‰ฅ55%) in SR, post-catheter ablation or cardioversion (โ‰ฅ3 months post-catheter ablation or cardioversion), no AF (\>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation), and with no new introduction of any new or increased dose of heart failure guideline-directed medical therapy (GDMT) (renin-angiotensin-aldosterone system inhibitors (RAASi), Sodium Glucose Co-transporter 2 (SLGT2) inhibitors, increased dose of beta-blocker (BB), mineralocorticoid receptor antagonist (MRA)) AF-pEF (Negative controls): * Age โ‰ฅ18 * Persistent AF before index catheter ablation or cardioversion * LVEF โ‰ฅ55% during rate-controlled (resting HR \<100bpm) AF. AIC-genotyping study, v1.7, 27.01.26 Page 13 of 28 AF/HF non-responders (Positive controls) * Age โ‰ฅ18 * Persistent AF before index catheter ablation or cardioversion * LVEF โ‰ค40% during rate-controlled (resting HR \<100bpm) AF before index catheter ablation or cardioversion. * Persistent LVSD (LVEF โ‰ค40%) in SR, post-catheter ablation or cardioversion (โ‰ฅ3 months post-catheter ablation or cardioversion), no AF (\>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation) and with no change in heart failure GDMT (RAASi, SGLT2 inhibitors, increased dose of BB, MRA). EXCLUSION: AIC (Cases). * No alternative cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy * Any pregnancy during AF or in the 12 months preceding LVSD onset. * Alcohol intake \>21 units/week * Any history of cardiotoxic chemotherapy AF-pEF (Negative controls) * No known cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy). * Any pregnancy during AF or in the 12 months preceding LVSD onset. * Alcohol intake \>21 units/week. * Any history of cardiotoxic chemotherapy. AF/HF non-responders (Positive controls) * No alternative cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy). * Any pregnancy during AF or in the 12 months preceding LVSD onset. * Alcohol intake \>21 units/week. * Any history of cardiotoxic chemotherapy.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
St Bartholomew's Hospital, Barts Health NHS Trust
London, United Kingdom
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy